{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:19:22Z","timestamp":1793848762894,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Millennium Health, LLC"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.drugalcdep.2018.07.023","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T16:30:48Z","timestamp":1535819448000},"page":"183-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS\/MS"],"prefix":"10.1016","volume":"193","author":[{"given":"Robert","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mikel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Hofilena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1258\/acb.2011.011116","article-title":"Screening for drugs of abuse: which matrix, oral fluid or urine?","volume":"48","author":"Allen","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1258\/0004563054255632","article-title":"Replacement of immunoassay by LC tandem mass spectrometry for routine measurement of drugs of abuse in oral fluid","volume":"42","author":"Allen","year":"2005","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0015","series-title":"National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","author":"American Society of Addiction Medicine (ASAM)","year":"2015"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0020","series-title":"Appropriate Use of Drug Testing in Clinical Addiction Medicine","author":"American Society of Addiction Medicine (ASAM)","year":"2017"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0025","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1176\/appi.ajp.2007.07050252","article-title":"Prescription OxyContin abuse among patients entering addiction treatment","volume":"164","author":"Carise","year":"2007","journal-title":"Am. J. Psychiat."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1515\/CCLM.2004.248","article-title":"Oral fluid as a diagnostic tool","volume":"42","author":"Choo","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1196\/annals.1384.037","article-title":"Interpretation of oral fluid tests for drugs of abuse","volume":"1098","author":"Cone","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jat\/26.8.541","article-title":"Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations","volume":"26","author":"Cone","year":"2002","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jat\/31.8.424","article-title":"Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid","volume":"31","author":"Cone","year":"2007","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jat\/bkt066","article-title":"Prescription opioids. II. Metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration","volume":"37","author":"Cone","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jat\/bkt031","article-title":"Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration","volume":"37","author":"Cone","year":"2013","journal-title":"J. Anal.Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0060","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jat\/bkv050","article-title":"Prescription opioids. IV. Disposition of hydrocodone in oral fluid and blood following controlled single-dose administration","volume":"39","author":"Cone","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/jat\/bku176","article-title":"Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration","volume":"39","author":"Cone","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.36076\/ppj.2014\/17\/63","article-title":"Utility of oral fluid in compliance monitoring of opioid medications","volume":"17","author":"Conermann","year":"2014","journal-title":"Pain Phys."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0075","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.drugalcdep.2006.08.020","article-title":"Oral Fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients","volume":"87","author":"Dams","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0080","series-title":"Proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs \u2013 Oral Fluid (94 FR 28054 - May 15, 2015)","author":"Department of Health and Human Services (DHHS)","year":"2015"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0085","series-title":"Counterfeit Prescription Pills Containing Fentanyls: a Global Threat. DEA-DCT-DIB-021-16 July 2016","author":"Drug Enforcement Administration (DEA)","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jsat.2007.12.006","article-title":"Evaluation of ongoing oxycodone abuse among methadone-maintained patients","volume":"35","author":"Dunn","year":"2008","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/anatox\/35.8.529","article-title":"Oral fluid drug testing of chronic pain patients. I. Positive prevalence rate of licit and illicit drugs","volume":"35","author":"Heltsley","year":"2011","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jat\/bkr019","article-title":"Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens","volume":"36","author":"Heltsley","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0105","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jat\/32.7.516","article-title":"Urinary buprenorphine concentrations in patients treated with Suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay","volume":"32","author":"Hull","year":"2008","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0110","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1373\/clinchem.2011.164822","article-title":"Oral fluid cannabinoids in chronic, daily cannabis smokers during sustained, monitored abstinence","volume":"57","author":"Lee","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0036933013482640","article-title":"Oral fluid as an alternative to urine testing for drugs of abuse in inpatient forensic settings: giving patients choice","volume":"58","author":"MacCall","year":"2013","journal-title":"Scot. Med. J."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jat\/bkr020","article-title":"Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry","volume":"36","author":"McMillin","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2016.01.027","article-title":"7-Aminoclonazepam is superior to clonazepam for detection of clonazepam use in oral fluid by LC-MS\/MS","volume":"455","author":"Melanson","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0130","series-title":"Increasing Co-occurrence of Fentanyl in the UDTs of Heroin-positive Healthcare Patients; Evidence of the Escalating National Epidemic","author":"Mikel","year":"2017"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsat.2017.01.005","article-title":"Urine drug testing results and paired oral fluid comparison from patients enrolled in long-term medication assisted treatment in Tennessee","volume":"76","author":"Miller","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0140","first-page":"69","article-title":"Drug testing and adherence monitoring in pain management: oral fluid testing","volume":"11","author":"Moore","year":"2015","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0145","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths involving fentanyl, fentanyl analogs, and U-47700 \u2014 10 States, July\u2013December 2016","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0379-0738(03)00045-8","article-title":"High prevalence of 6-acetylmorphine in morphine-positive oral fluid specimens","volume":"133","author":"Presley","year":"2003","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0155","series-title":"Oral Fluid Reveals More Heroin Use Than Previously Believed, According to Quest Diagnostics Drug Testing Index","author":"Quest Diagnostics News Release","year":"2011"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/ADM.0000000000000258","article-title":"Definitive LC-MS\/MS drug monitoring impacts substance-use treatment planning and patient outcomes: a brief report","volume":"10","author":"Rzetelny","year":"2016","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0165","series-title":"Clinical Drug Testing in Primary Care. Technical Assistance Publication (TAP) Series 32","first-page":"12","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2012"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0170","series-title":"Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.07.023_bib0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/anatox\/35.1.32","article-title":"Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with methadone or buprenorphine","volume":"35","author":"Vindenes","year":"2011","journal-title":"J. Anal. Toxicol."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618304861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618304861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T04:07:43Z","timestamp":1661918863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618304861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":35,"alternative-id":["S0376871618304861"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.023","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}